Introduction
An annual seasonal influenza vaccine is the main protection against influenza infection and its complications. 1 Influenza infections have increased morbidity among HIV-infected children and adults, including pregnant women. This underscores the importance of vaccine-conferred protection. However, the effectiveness of the influenza vaccine depends on at least 2 factors, the characteristics of the vaccinated person (eg, their age and health) as well as the match between the influenza vaccine strain and the circulating strain spreading in the community at that time. 2 HIV infection is a characteristic of a vaccinated person that can influence vaccine-conferred protection. Multiple studies have shown a poor antibody response to influenza vaccines in HIV-infected individuals. [3] [4] [5] [6] A previous study demonstrated only 38% of children had a complete seroprotective response of all strains of trivalent influenza vaccine (TIV) at both 1 month and 6 months. 7 However, some studies demonstrated that the proportion of HIV-infected children generating a seroprotective response after influenza vaccination was as high as 79%. To perform nucleotide sequencing, total RNA was extracted using a QIAamp viral RNA mini kit (Qiagen) from direct nasal swab specimens of a vaccinated person who had developed a PCR-confirmed influenza illness from the 2009 pandemic virus. The RNA sample was amplified for the complete influenza HA gene, and the amplified product was subjected to nucleotide sequencing. The sequence was edited, aligned, and translated into an amino acid sequence by BioEdit program (version 7.1.11; available at http://www.mbio.ncsu.edu/ bioedit/bioedit.html). The sequence was submitted to the GenBank database with the accession number of KU144591. Table 1 There are several interesting characteristics of the vaccinated person in the present case. First, she was 17 years old. The seroprotection of TIV among HIVinfected children is reported to be low. A previous double-blinded, placebo randomized controlled trial of 410 young HIV-infected children demonstrated that the proportions of TIV-vaccinated children seroconverting after a second dose against the vaccine strains of H1N1, H3N2, and influenza B were as low as 47.5%, 50%, and 40%, respectively. 10 However, a previous systematic review reported that TIV prevented laboratory-confirmed influenza with a pooled efficacy as low as 11% in young children and as high as 85% in adults. 11 Second, the influenza A virus symptom of the present case occurred 216 days after TIV vaccination was given. The durability of the seroprotection for influenza vaccine often spans only an estimated 180 days. 12 Third, she had a confirmed HIV infection. Thus, the response to the vaccine may have depended on the B-cell subset distribution rather than CD4 counts or viral load. 13 The present case had a high CD4 count and viral suppression. Fourth, she had a high body mass index. The previous study demonstrated that a high body mass index was associated with a greater decline in influenza antibody titers at 12 months post TIV.
14 Obesity may impair the ability to mount a protective immune response to influenza virus.
Conclusion
The closer relationship between the causative virus and the circulating strains, the low seroprotection of TIV among HIV-infected children, the durability of seroprotection against influenza vaccine that often spans only an estimated 180 days, and obesity may have reduced the effectiveness of the influenza vaccine in the present case.
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